title: New Therapeutic Approaches for Waldenstrom Macroglobulinemia.
abstract: Waldenstrom Macroglobulinemia (WM) is a B-cell disorder characterized by the infiltration of the bone marrow (BM) with lymphoplasmacytic cells, as well as detection of an IgM monoclonal gammopathy in the serum. WM is an incurable disease, with an overall medial survival of only 5-6 years. First-line therapy of WM has been based on single-agent or combination therapy with alkylator agents (e.g. chlorambucil or cyclophasphamide), nucleoside analogues (cladribine or fludarabine), and the monoclonal antibody rituximab. Novel therapeutic agents that have demonstrated efficacy in WM include thalidomide, lenalidomide, bortezomib, everolimus, Atacicept, and perifosine. The range of the ORR to these agents is between 25-80%. Ongoing and planned future clinical trials include those using PKC inhibitors such as enzastaurin, new proteasome inhibitors such as carfilzomib, histone deacetylase inhibitors such as panobinostat, humanized CD20 antibodies such as Ofatumumab, and additional alkylating agents such as bendamustine. These agents, when compared to traditional chemotherapeutic agents, may lead in the future to higher responses, longer remissions and better quality of life for patients with WM.
authors.affiliation: Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, 02115 USA.
authors.forename: Jennifer
authors.initials: J
authors.lastname: Stedman
authors.forename: Aldo
authors.initials: A
authors.lastname: Roccaro
authors.forename: Xavier
authors.initials: X
authors.lastname: Leleu
authors.forename: Irene M
authors.initials: IM
authors.lastname: Ghobrial